Abstract A randomized, double-blind, placebo-and active-controlled multicentre study with spirapril, a new angiotensin-converting enzyme inhibitor (ACEI), has been conducted in patients with chronic congestive heart failure (CHF) of NYHA classes II-IV. After a placebo run-in period of 1-4 weeks, patients were randomly assigned to one of five treatment groups: placebo (n = 48), spirapril 1.5 mg (n = 48), spirapril 3 mg (n = 53), spirapril 6 mg (n = 51) or enalapril 5/10 mg (n = 48). The primary objective was to assess changes in exercise tolerance, and the secondary objective was an assessment of cardiovascular signs and symptoms, quality of life, ejection fraction and chest X-ray findings.
Spirapril is a new carboxyl-bearing angiotensin-converting enzyme inhibitor (ACEI). It is a prodrug, which after oral administration is rapidly and extensively metabolized to the active form spiraprilate [30] . It has been described as having a balanced hepatic/renal excretion [13, 16] , a characteristic which makes the drug promising [14] for the treatment of congestive heart failure (CHF), a syndrome which is often accompanied by impaired renal function. After the demonstration of short-term haemodynamic responses with this drug [31] , the CASSIS trial was designed to evaluate the long-term efficacy, safety and tolerability of various doses of spirapril compared with placebo and enalapril in patients with symptomatic heart failure.
Subjects and methods
The trial was performed between January 1990 and September 1991 in 18 centres in the Czech and Slovak Republics (see Appendix) in compliance with the guidelines for Good Clinical Practice, as laid down by the European Community. The protocol received approval from the respective Czechoslovak authority and all patients gave their informed consent before entering the study. During the trial an Independent Review Panel (IRP) was formed to monitor the mortality and to possibly allow a formal recommendation for early cessation in the case of excessive differences being demonstrated. Only the IRP members had access to the treatment codes before the final lock of the database. The main inclusion criteria were: CHF secondary to coronary heart disease (CHD) or dilated cardiomyopathy (DCMP), the ability to perform an exercise tolerance test for at least 2 min, but not more than 14 rain, and either a left ventricular ejection fraction of less than 40% or a cardiothoracic ratio of greater than 0.55. Patients with other causes of CHF, a history of acute myocardial infarction (MI) within the previous month or uncontrolled hypertension were excluded. Further exclusion criteria comprised unstable angina pectoris, a history of clinically relevant arrhythmias, hypotension (systolic blood pressure < 90 mmHg), uncontrolled diabetes mellitus, clinically relevant renal, hepatic, gastrointestinal, neurological or haematological diseases, a serum creatinine concentration >180 mmol/1 and a history of hypersensitivity to ACEI. Disallowed medications constituted inotropic agents other than digitalis and agents with vasodilating properties; however, the use of nitrates and calcium channel blockers was permitted in patients with angina. The dosage of concomitant digitalis and diuretics was to be maintained unchanged throughout the study, and potassiumsparing diuretics and potassium supplements were allowed, if necessary, provided there was close surveillance of their use.
Design dard deviation of 4 min and a power of 80% to detect a real difference, the optimal sample size was estimated as 50/group. After completion of half of the sample, an interim analysis was planned. In addition, an IRP continuously monitored the mortality using a sequential model to allow for early cessation in the case of excess differences. The IRP proposed the comparison of all the spirapril groups pooled with placebo and with enalapril; the respective boundaries were equivalent to an overall probability of 0.025; however, these boundaries were not crossed during the study period; thus, the conduct of the trial was not affected.
Changes from baseline were analysed using the paired t-test and Wilcoxon's signed rank sum test. Between group comparisons were performed as overall tests using analysis of covariance and the Mann-Whitney rank sum test, and categorical data were analysed using the )~2-test and Fisher's two-tailed Exact test. For exploration purposes baseline and outcome parameters were analysed using a multiple linear correlation matrix.
After an initial placebo phase of 1 4 weeks, eligible patients were randomized to one of five parallel groups: placebo, 1.5 mg, 3 mg or 6 mg spirapril, or enalapril. The double-blind treatment period was 12 weeks. The study medication was to be taken as one capsule every morning before breakfast; however, the patients were. instructed not to take the study medication on the day of a scheduled visit. Patients randomized to enalapril started with 5 mg once a day, and switched to 10 mg once a day in week 3.
Parameters
The primary efficacy criterion was the change in exercise duration from baseline to endpoint. This test was to be performed on a programmable, electronically braked bicycle (Ergometrics 900, Ergoline), starting with a workload of 25 W and increasing by 10 W every 2 rain. Before switching to a new stage, blood pressure, heart rate and ECG were recorded automatically. The test was performed in the sitting position, and it was scheduled twice (to be repeated if the difference was > 90 s) during the placebo phase and twice during the double-blind phase. The exercise test was stopped either by the patient due to intolerable symptoms, or by the investigator according to the accepted safety criteria. Exact duration and reasons for stopping were recorded.
Secondary efficacy parameters comprised cardiovascular signs and symptoms and a respective sum score (CV-SSS), New York Heart Association (NYHA) functional class, quality of life (QoL, "Living with Heart Failure" questionnaire [22] ), left ventricular ejection fraction (LVEF) by two-dimensional echocardiography, and the cardiothoracic ratio (CTR) assessed by chest X-ray (CXR). After completion of the study, but before breaking the codes, available chest X-ray images (81% of all patients completing the study) were classified for signs of lung congestion by a new scoring system [27] . Furthermore, mortality, discontinuations, serious cardiovascular adverse events (SCVAEs) and frequency and duration of unscheduled hospitalizations were analysed. Compliance was checked regularly by capsule counting.
Safety
Adverse events were recorded on occurrence. Heart rate, blood pressure, ECG and blood samples for standard biochemical and haematological parameters were taken at 3-week intervals.
Statistical methods
For the estimation of sample size the average improvement in the exercise duration was estimated to be at least 2 min when comparing placebo and the highest dose. Together with an assumed stan-
Results

Patient characteristics
A total of 275 patients were screened, and a total of 248 patients were randomized. The main reason for non-inclusion was exceeding the upper limit of exercise duration. Heart failure was in an advanced stage in the majority of patients (Table 1) . Few significant differences in baseline characteristics were detected: concomitant nitrates (less frequent in the placebo group and more frequent in the 1.5 mg spirapril and the 3 mg spirapril groups), antiplatelet drugs (less on placebo, more on 6 mg spirapril), calcium channel blockers (more frequent in the 1.5 mg spirapril group). The usual background and efficacy parameters showed no differences between the groups at baseline. On average, the patients were prescribed three to five other drugs concomitantly. Throughout the double-blind period more than 97% of the patients complied with the regimen for study medication.
Discontinuations and mortality
During the double-blind phase of the trial, a total of 22 patients discontinued the trial prematurely, there of 13 due to cardiovascular death, either dying suddenly or after serious worsening of CHF. In addition, one patient randomized to enalapril experienced a fatal traffic accident, and one further patient randomized to enalapril died 8 weeks after discontinuation due to worsening of CHF. The overall as well as the cardiovascular mortality was significantly different between all ACE! recipients and placebo (P = 0.023), between all spirapril recipients and placebo (P = 0.025), and between 3 mg spirapril alone and placebo (P = 0.01, all P by Fisher's Exact test, see Tables 2, 3) . No evidence was found to suggest a different incidence of sudden deaths, or death following obvious worsening of CHF. The number of serious cardiovascular adverse events, the frequency and duration of unscheduled hospitalizations, and the number of patients with newly prescribed or increasing dosage of concomitant cardiovascular medication were lower in all spirapril than in placebo or enalapril recipients. These differences were small for isolated features; however, when pooled they became significant (P = 0.015; Table 3 ).
Exercise tolerance
The patients' average exercise capacity at baseline was 8 min; the workload at that stage was 65 W. The exercise duration significantly improved in all treatment groups compared to baseline, the absolute and relative changes being greatest with 6 mg spirapril and enalapril; however, no statistically significant difference from placebo was observed in any between group comparison ( Fig. 1 ).
An exploratory analysis revealed some factors which might have interacted with the ACEI treatment, and thus might have confounded positive effects upon the exercise tolerance. In particular, pre-existing angina, angina during the baseline exercise tolerance test, or the concomitant use of any calcium-channel blocker and of nifedipine showed significant negative correlations with the exercise duration, i.e. patients with these cofactors showed no or even a negative response to ACEI treatment, whereas patients without these factors improved (Fig. 2a, b) . In the subgroup of patients without angina at baseline (the most frequent confounding factor), a marginally significant difference was detected between the response to 6 mg spirapril and placebo. The use of nifedipine was highly correlated with pre-existing angina; on the other hand, nifedipine was a stronger marker of an unfavourable response to ACEI than history of angina (Table 4) . Other calcium-channel blockers (verapamil and diltiazem) were not used as frequently; nevertheless, they did not seem to be responsible for the different outcome. Interactions of angina or nifedipine with any other efficacy or safety parameter were not found.
Secondary efficacy parameters
The other parameters showed marked improvements without significant differences between the groups (Table 5) . Regarding left ventricular ejection fraction, only the active groups showed significant differences from baseline; however, no between group comparison became significant. Both the cardiovascular signs and symptom score and the Quality of Life score improved most markedly in the group on 1.5 mg spirapril; however, the 6-rag spirapril and enalapril groups showed no difference from placebo.
In contrast to the above were the findings with the CXR. Only in patients on spirapril was the mean relative heart size reduced versus baseline. The response was marginally significantly different between all spirapril patients pooled and placebo. In the blinded, centralized re-analysis of the CXR images, significantly more improvements in lung congestion were observed with 6 mg spirapril than with placebo. The effect seemed to be dose dependent (Fig. 3) .
Safety
Nearly half of all adverse events and most of the serious adverse events were related to the underlying disease. Due to the overwhelming cardiovascular character of the adverse events, the overall incidence was slightly lower in actively treated groups than under placebo (Table 6 ). Only few adverse events were considered by the investigators to be related to study medication: one case of symptomatic hypotension with 1.5 mg spirapril and two with 6 mg spirapril, one case of coughing with 3 mg spirapril and one with enalapril, two cases of anaemia with enalapril and, finally, two cases of hyperkalaemia with enalapril. From the regular cardiovascular evaluation, however, no evidence for increased coughing under ACEI was found; the data rather support the assumption of improvements under active treatment. There were no consistent or clinically relevant changes in the heart rate, whilst there was a trend for a slight reduction in systolic blood pressure, on average by 3 mmHg, in actively treated patients.
Among the 48 regularly assessed laboratory parameters only very slight changes were detected. Some became significant, although they were not considered to be clinically relevant. Serum potassium increased slightly in patients on 6 mg spirapril and enalapril, on average by 3%-6%, corresponding to about 0.2 mmol.1-1. The analysis of changes beyond the normal range revealed no difference from placebo (one to four cases per group per visit). Haematocrit values decreased throughout all visits in the group treated with 6 mg spirapril, the average changes from baseline being -2.2%, -3.7% and -3% for weeks 3, 6 and 12, respectively. The median changes were in the same range. Erythrocyte counts decreased on average by 3% during the treatment with 6 mg spirapril.
Discussion
In recent years several survival studies have demonstrated that ACEIs represent a major therapeutic breakthrough in the treatment of severe CHF [7] , mild to moderate CHF [6, 25] , prevention of CHF [26] and after myocardial infarction [1, 20] , although one very large trial on the latter indication failed to show a favourable effect [29] . The mortality results from the present study are in line with these prospective investigations, whereas a point estimate for mortality reduction under spirapril would be erroneous due to the low sample size. In CHF trials the mortality rate in the control group as well as the difference from active treatment varied within a wide range depending on the protocol characteristics. In some trials [4, 10, 23, 25, 28] , the mortality rate in the placebo group was lower than in the CASSIS; however, in other trials it was even higher [7, 17] . Also, regarding the difference in mortality rate during the first 12 weeks between active and placebo, the CASSIS was in the mid range; two studies, [17, 28] detected a more pronounced difference, and four trials [4, 7, 10, 25 ] a lower one.
The main mechanism of action of ACEIs is believed to be peripheral vasodilation through removal of the vasoconstrictor angiotensin IX leading to a reduction in pre-and afterload [8] . It has also been reported that ACEIs inhibit aldosterone secretion and reduce circulating norepinephrine levels [18] , and exert an effect on growth factor, myocardial tissues and vessel walls; thus, they slow down the progress of structural changes in heart dilatation [19] . Indeed, the results of the present trial provide evidence for a reduction of heart size as this was observed only in spirapril-treated patients. More noteworthy, however, were the improvements in lung congestion observed in a subset of spirapril patients.
No significant effect of either spirapril or enalapril on exercise tolerance has been found. Due to the enthusiasm about the benefits of ACEI therapy provoked by marked improvements published at the time of planning of our trial [2, 3, 24] , the differences in exercise tolerance between the treatments were overestimated. Hence, prospective rules to adjust for premature discontinuations, deaths and cardiovascular adverse events were not implemented; indeed, such rules would have brought about significant differences, as in a recently published double-blind withdrawal study with quinapril [21] . The lack of adjustment rules might partly explain the ineffectiveness of ACEIs observed in large trials with enalapril (substudy of the SOLVD treatment arm [25] , V-HeFT II [6] ), with ramipril [28] and with captopril [15] .
A second confounding factor might have been the unsatisfactory response in patients with angina or those receiving concomitant nifedipine. Comparable observations have previously been made with captopril [5] . Despite the concerns of many authors about the use of calcium antagonists in patients with CHF [9, 12] , their use is widespread for this indication. Notably in the SOLVD treatment trial as many as 30% of the patients received concomitant calcium-channel blockers [25] . In our study, the most frequently used calcium-channel blocker was nifedipine. The assumed interaction with ACEI was also present in all recipients of calcium-channel blockers, although it was not as strong as when nifedipine recipients alone were considered. It is unclear whether the underlying mechanism is a direct interaction between ACEI and nifedipine, or whether nifedipine was just a good marker for non-responders due to angina. On the other hand, neither an effect on anginal complaints was detected in the respective regularly evaluated score nor on other cardiovascular signs and symptoms. The findings of this study underline that the indication for calcium-channel blockers in patients with CHF should be considered carefully [11] .
Another interesting finding of this study might be that the lower doses clearly improved the clinical symptoms and the quality of life more than the highest dose of spirapril or enalapril. It has to be remembered, however, that these two parameters are highly correlated, so that a chance finding in the one would probably appear in the other. On the other hand, the lower efficacy of enalapril on these parameters might be a reflection of the relatively high number of adverse events.
In conclusion, the results of our study indicate that spirapril might be effective in prolonging survival in patients with CHF. It reduces heart size, improves X-ray signs of lung congestion and is well tolerated. On the other hand, both spirapril and enalapril induce only minor effects in exercise capacity, especially in patients with angina pectoris, and/or on nifedipine treatment. Overall, spirapril can be considered a welltolerated and effective drug for long-term treatment of chronic CHF.
